Brind.
From Executive Order Accelerates Research into Psychedelic Therapies

How does Executive Order accelerating psychedelic research affect National Institutes of Health?

NIH NIDA to fund research into ibogaine for OUD and PTSD The Executive Order establishing the accelerated research framework has led to specific funding mandates for the National Institute on Drug Abuse (NIDA), a branch of the NIH. NIDA has committed to funding research into ibogaine, a plant-derived psychoactive drug. This funding is specifically earmarked for studies targeting opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) in adults.

Reported by 12 independent outlets Written Oct 6
Effect
Strong positive
How direct
2 steps, 1 inferred by Brind
When
Right away
The story
Gone quiet

How it reaches National Institutes of Health

Reported by news outletsBrind's reasoning

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • The Executive Order accelerated psychedelic drug availability, prompting evaluation of ibogaine for OUD and PTSD.raps.org
  • The National Institute on Drug Abuse (NIDA) will fund research on ibogaine to treat opioid use disorder (OUD) and post-traumatic stress disorder (PTSD).raps.org

Why it matters

For the NIH, this funding mandate through NIDA signifies a major shift in its research priorities, moving into the highly experimental field of psychedelic medicine. This focus on ibogaine allows the NIH to pursue novel treatments for conditions like OUD and PTSD that have proven resistant to traditional care.

What we don't know yet

  • What are the specific criteria for the successful evaluation of ibogaine in these trials?
  • How will the NIH ensure the highest standards of safety and efficacy are met during this accelerated research?

Is this still moving?

Gone quiet Reached 4 outlets in its first 24 hours
Reports
21
Developments
6
Repetition
81%

What would change this answer

The FDA approves a specific trial design for ibogaineThe NIH funding could be tied to the successful execution of the FDA-approved protocol, leading to clearer research outcomes.
The NIH secures additional funding for NIDAThe scope and scale of the research into ibogaine could be significantly expanded, allowing for larger trials.

— Other considerations

Beyond this explainer

Questions worth asking

Ideas the web ties closely to this story that the explainer doesn't mention. These are prompts for your own research: Brind hasn't answered them.

  • About Buprenorphine

    How might the research into ibogaine compare to existing treatments like buprenorphine for opioid use disorder?

  • About Obsessive Compulsive Disorder

    Since the NIH is studying ibogaine for PTSD, could this research also be adapted to treat obsessive compulsive disorder?

  • About Alcohol Use Disorder

    Given the focus on substance use disorders, is the NIH also evaluating psychedelic treatments for alcohol use disorder?

Explore connected ideas

Each opens in Related concepts: what the web connects to it, with Brind's news on it.

The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.

Reporting

All 12 outlets

Keep going

The full eventExecutive Order Accelerates Research into Psychedelic Therapies Everything aboutNational Institutes of Health

Brind's analysis is written by AI from the reporting linked above and can be wrong. It is not investment advice; do your own research.